TY - JOUR
T1 - Is Proflavine Exposure Associated with Disease Progression in Women with Cervical Dysplasia? A Brief Report
AU - Pantano, Naitielle
AU - Hunt, Brady
AU - Schwarz, Richard A.
AU - Parra, Sonia
AU - Cherry, Katelin
AU - Possati-Resende, Júlio César
AU - Longatto-Filho, Adhemar
AU - Fregnani, José Humberto Tavares Guerreiro
AU - Castle, Philip E.
AU - Schmeler, Kathleen
AU - Richards-Kortum, Rebecca
N1 - Funding Information:
Research reported in this publication was supported by the NCI of the NIH under Award Numbers UH2CA189910, UH3CA189910 and CA016672. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
Publisher Copyright:
© 2018 The Authors. Photochemistry and Photobiology published by Wiley Periodicals, Inc. on behalf of American Society for Photobiology
PY - 2018/11/1
Y1 - 2018/11/1
N2 - Proflavine is an acridine dye used with high-resolution microendoscopy for in vivo diagnostic evaluation of cervical epithelial cells. However, there are concerns that even short-term exposure of cervical tissue to dilute proflavine may increase cervical cancer risk. We performed a retrospective analysis of women referred for colposcopy to Barretos Cancer Hospital comparing the risk of cervical disease progression in those whose cervical tissue was (n = 232) or was not exposed (n = 160) to proflavine. Patients in both groups underwent treatment and follow-up based on histopathologic results and per the local standards of care. Progression of disease was evaluated by comparing histopathology from the initial visit to the worst subsequent histopathology result from all follow-up visits. Mean duration of follow-up was 18.7 and 20.1 months for the proflavine-exposed and controls groups, respectively. There were no significant differences in disease progression from normal/CIN1 to CIN2/3 or from any initial diagnosis to invasive cancer between the proflavine exposed and control groups overall. Risks of cervical dysplasia progression observed in this study are in agreement with those of the natural history of cervical cancer. Our results suggest that cervical exposure to dilute proflavine does not increase the risk of cervical precancer and cancer.
AB - Proflavine is an acridine dye used with high-resolution microendoscopy for in vivo diagnostic evaluation of cervical epithelial cells. However, there are concerns that even short-term exposure of cervical tissue to dilute proflavine may increase cervical cancer risk. We performed a retrospective analysis of women referred for colposcopy to Barretos Cancer Hospital comparing the risk of cervical disease progression in those whose cervical tissue was (n = 232) or was not exposed (n = 160) to proflavine. Patients in both groups underwent treatment and follow-up based on histopathologic results and per the local standards of care. Progression of disease was evaluated by comparing histopathology from the initial visit to the worst subsequent histopathology result from all follow-up visits. Mean duration of follow-up was 18.7 and 20.1 months for the proflavine-exposed and controls groups, respectively. There were no significant differences in disease progression from normal/CIN1 to CIN2/3 or from any initial diagnosis to invasive cancer between the proflavine exposed and control groups overall. Risks of cervical dysplasia progression observed in this study are in agreement with those of the natural history of cervical cancer. Our results suggest that cervical exposure to dilute proflavine does not increase the risk of cervical precancer and cancer.
UR - http://www.scopus.com/inward/record.url?scp=85056358361&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85056358361&partnerID=8YFLogxK
U2 - 10.1111/php.12976
DO - 10.1111/php.12976
M3 - Comment/debate
C2 - 29981148
AN - SCOPUS:85056358361
SN - 0031-8655
VL - 94
SP - 1308
EP - 1313
JO - Photochemistry and Photobiology
JF - Photochemistry and Photobiology
IS - 6
ER -
